September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
6 citations
,
January 2025 in “RSC Medicinal Chemistry” Targeting the RAAS with small molecules can improve cardiovascular disease treatments.
14 citations
,
March 2019 in “European journal of pharmaceutics and biopharmaceutics” Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
13 citations
,
October 2017 in “Bioorganic & Medicinal Chemistry” Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
180 citations
,
July 1973 in “The New England Journal of Medicine” Minoxidil effectively lowers blood pressure with few side effects.
38 citations
,
April 2018 in “Psychopharmacology/Psychopharmacologia” Blocking CRF-R1 can reduce alcohol intake in stressed mice.
1 citations
,
March 2020 in “Journal of Pharmacological Sciences” Benzothiazepines like diltiazem reduce anxiety in mice by making neurosteroids.
October 2024 in “Internal Medicine” Stopping nalfurafine reversed hair loss in a hemodialysis patient.
9 citations
,
June 2021 in “Journal of Inflammation Research” Euph E and Euri A from Euphorbia neriifolia help control inflammation and immune response in cells.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
55 citations
,
March 1973 in “PubMed” Minoxidil is a new drug that lowers blood pressure.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
44 citations
,
May 2008 in “Plant journal” D'orenone stops root hair growth by disrupting auxin transport, but adding auxin can reverse this.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
October 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” DA-9401 can protect against finasteride-induced reproductive damage in rats.
July 2025 in “Journal of Investigative Dermatology” 65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
April 2017 in “The Journal of urology/The journal of urology” Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
January 2019 in “Urology Practice” Urologists prescribe newer medications more often than primary care physicians, who could benefit from more education on treatment options.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
73 citations
,
September 2016 in “Journal of Translational Medicine” Some heart drugs show promise for other conditions, but more research is needed to confirm their effectiveness and safety.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
19 citations
,
March 2022 in “Journal of Infection” Canakinumab's effect on COVID-19 outcomes is unclear.